Table 4.

Best overall response to treatment

Response, n (%)ENC + CTX, n = 26ENC + ALP + CTX, n = 28
Complete response (CR)1 (3.8)0
Partial response (PR)4 (15.4)5 (17.9)
Stable diseasea (SD)15 (57.7)21 (75.0)
Progressive disease (PD)4 (15.4)1 (3.6)
Unknown2 (7.7)1 (3.6)
Overall response rate (CR + PR)5 (19.2)5 (17.9)
Disease control rate (CR + PR + SD)20 (76.9)26 (92.8)
  • Abbreviations: ENC + ALP + CTX, encorafenib combined with alpelisib and cetuximab; ENC + CTX, encorafenib combined with cetuximab.

  • aIn the ENC + CTX group, 1 patient with SD had unconfirmed PR, and 4 patients in the ENC + ALP + CTX group with SD had unconfirmed PR.